• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Field Trip Health Ltd. to Pursue Treatment Resistant Depression and Postpartum Depression as Indications for FT-104

    9/9/21 7:30:00 AM ET
    $FTRP
    Get the next $FTRP alert in real time by email

    TORONTO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX:FTRP, FTRP.WT, NASDAQ:FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today the lead indications for FT-104, its novel psychedelic compound in development, will be Treatment Resistant Depression (TRD) and Postpartum Depression (PPD). Field Trip today also announced that Anita H. Clayton, MD, Chair of Psychiatry and Neurobehavioral Sciences at the School of Medicine at the University of Virginia, has joined its Scientific Advisory board.

    Through Field Trip Discovery, its drug development division, Field Trip is developing next-generation psychedelic molecules. Its first molecule in development, FT-104, a prodrug, is a synthetic serotonin-2A (5HT2A) agonist whose active component has serotonin-2A potency similar to psilocybin. Importantly, however, the active component of FT-104 is expected to produce a reliably shorter duration of psychoactivity (2-3 hours) than psilocybin, and has high bioavailability after administration.

    Preclinical activities that will enable commencement of Phase I clinical trials in calendar Q1 2022 are ongoing and are expected to continue through to the end of calendar 2021. After completion of the Phase 1 and opening of a US-IND, Field Trip intends to initiate Phase IIA studies in TRD, following which Phase II studies in TRD and PPD are expected to be conducted substantially in parallel.

    Treatment Resistant Depression

    It is estimated that, globally, there are 322 million people who suffer from major depressive disorders1, of which approximately 33%, or 100 million people, meet the diagnostic criteria for TRD. There are few alternatives for people suffering with TRD and those who are diagnosed with TRD have typically failed first and second line therapies, thus TRD represents a significant unmet need for effective treatments. Beyond the quality of life impacts, people with TRD have higher costs of care and tend to experience decreased work productivity.

    Postpartum Depression

    Postpartum depression affects about 10-15% of all mothers of newborns, with an estimated prevalence of 400,000 diagnosed patients in the U.S. per year.2 The only currently approved therapy for PPD requires a significant time commitment away from family and newborn (2.5-3 days) while serotonin reuptake inhibitors (SSRIs) used off-label take a long time for onset and only show limited efficacy. This represents a potential concern for the safety, well-being and long-term development of the child.3  

    Dr. Nathan Bryson, Field Trip's Chief Scientific Officer, said, "Given our encouraging preclinical results to date, we believe that FT-104 has the potential to transform approaches to hard-to-treat depressive disorders. Our preclinical activities are expected to continue through 2021 with the goal of determining the pharmacokinetics, metabolism and routes of elimination in animal species, as well as safety pharmacology. Selecting our two main indications is a significant milestone for Field Trip, and will guide our clinical strategy as we design our Phase II trials and work toward drug commercialization."

    Joseph del Moral, Field Trip's CEO, said, "The decision to pursue TRD and PPD in parallel is the result of a comprehensive strategic assessment of FT-104's unique and desirable characteristics. TRD represents a tremendous market opportunity for which we believe FT-104 will rapidly become a preferred treatment option, especially relative to psilocybin. Notably, PPD is an acute condition with a lower regulatory burden and shorter overall timelines for approval making FT-104 a potential first-in-class for PPD. By pursuing TRD and PPD in parallel, we can achieve both speed and scale for FT-104."

    "We are also delighted that Dr. Clayton has joined our Advisory board. She is a widely known and highly respected physician for the treatment of depression and PPD and our future work will benefit from her extensive knowledge," concluded Mr. del Moral.

    Appointment of Anita H. Clayton, MD

    Anita H. Clayton, MD is the David C. Wilson Professor and Chair of Psychiatry & Neurobehavioral Sciences and Professor of Clinical Obstetrics & Gynecology at the University of Virginia. She has published over 200 peer-reviewed papers, and was named to the 2019-2020 Best Doctors in America list. She has focused her clinical practice and research on major depressive disorder, mood disorders associated with reproductive-life events in women including PPD, sexual dysfunction, and sexual disorders.

    "A significant population of patients with depressive disorders do not find adequate symptom management from the current options. Major depressive disorder (MDD), treatment-resistant depression (TRD) and postpartum depression (PPD) share similar etiologies and negatively impact functioning. Women are twice as likely as men to be diagnosed with depression, and a significant unmet need exists for TRD and PPD. Fast-acting medicinal agents that provide immediate and long-lasting relief are critically lacking. I am looking forward to examining whether the serotonin agonist compound, FT-104, may have such effects," added Dr. Clayton.

    About Field Trip Health Ltd.

    Field Trip is a global leader in the development and delivery of psychedelic therapies. With our Field Trip Discovery division leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics and our Field Trip Health division building centers for psychedelic therapies opening across North America and Europe along with the digital and technological tools that will enable massive scale, we help people in need with a simple, evidence-based way to heal and heighten engagement with the world.

    Learn more at https://www.meetfieldtrip.com, https://www.fieldtriphealth.com and https://www.fieldtriphealth.nl.

    Follow us on Twitter and Instagram: @fieldtriphealth

    To receive company updates about Field Trip and to be added to the email distribution list please sign up here.

    Cautionary Note Regarding Forward-Looking Information

    This release includes forward-looking information (within the meaning of Canadian securities laws and within the meaning of the United States Private Securities Litigation Reform Act of 1995) regarding Field Trip and its business. Often but not always, forward-looking information can be identified by the use of words such as "expect", "intends", "anticipated", "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would" or "will" be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of Field Trip, and are based on assumptions and subject to risks and uncertainties. Although the management of Field Trip believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including interest in Field Trip's training program, interest in the KAP Co-Op Program, uptake of the KAP Co-Op Program by therapists and patients, the timing and results of its research and development programs, whether related to TRD, PPD or otherwise, approval of phase 1 human trials, if any, the risk that future clinical studies may not proceed as expected or may produce unfavorable results, the opening of additional clinics, the COVID-19 epidemic, the medical clinic industry, market conditions, economic factors, management's ability to manage and to operate the business and the equity markets generally. Although Field Trip has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Field Trip does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

    This press release does not constitute an offer to sell or the solicitation of an offer to buy securities.

    Neither the Toronto Stock Exchange, nor its Regulation Services Provider, have approved the contents of this release or accept responsibility for the adequacy or accuracy of this release.

    Media contacts:

    McKenna Miller

    KCSA Strategic Communications

    347-487-6197

    [email protected]

    Rachel Moskowitz

    Autumn Communications

    202-276-7881

    [email protected]

    Investor contacts:

    Kathleen Heaney

    KCSA Strategic Communications

    [email protected]

    SOURCE Field Trip Health Ltd.

    1 https://jamanetwork.com/journals/jama/article-abstract/2618635

    2 Gavin NI, Gaynes BN, et al. Obstetrics & Gynecology 2005, 106, 1071.

    3 Murray L, Cooper PJ Int. J Psychiatry 1996, 8, 55.



    Primary Logo

    Get the next $FTRP alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $FTRP

    DatePrice TargetRatingAnalyst
    11/22/2021$20.00 → $25.00Buy
    HC Wainwright & Co.
    9/1/2021$20.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $FTRP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Field Trip Health with a new price target

      HC Wainwright & Co. reiterated coverage of Field Trip Health with a rating of Buy and set a new price target of $25.00 from $20.00 previously

      11/22/21 6:28:20 AM ET
      $FTRP
    • HC Wainwright & Co. initiated coverage on Field Trip Health with a new price target

      HC Wainwright & Co. initiated coverage of Field Trip Health with a rating of Buy and set a new price target of $20.00

      9/1/21 6:13:30 AM ET
      $FTRP

    $FTRP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Reunion Neuroscience Inc. to Commence Trading on the Toronto Stock Exchange on August 17, 2022

      TORONTO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (formerly, Field Trip Health Ltd., the "Company" or "Reunion"), a global leader in the discovery and development of innovative of psychedelic-inspired therapeutics for improved mental health outcomes, is pleased to announce that its common shares (the "Shares") will commence trading on the Toronto Stock Exchange ("TSX") under the ticker symbol "REUN" at the opening of the market on August 17, 2022. Trading of the Company's shares on the TSX represents the last step in the corporate reorganization that resulted in the spinout of the Company's former subsidiary, Field Trip Health & Wellness Ltd. ("FTHW") into a stand-alone

      8/16/22 12:46:16 PM ET
      $FTRP
    • Reunion Neuroscience Inc. (Formerly Field Trip Health Ltd.) Reports Fiscal First Quarter 2023 Financial Results, Completed Corporate Reorganization on August 11, 2022

      Completed corporate reorganization, separating the Field Trip Discovery and Field Trip Health divisions into two separate companies.Field Trip Discovery renamed Reunion Neuroscience Inc. ("Reunion" or the "Company"), and will remain listed on the NASDAQ Stock Market and Toronto Stock Exchange under new ticker symbol "REUN".Field Trip Health renamed Field Trip Health & Wellness Ltd. ("Field Trip H&W") and has received listing approval from the Toronto Stock Exchange Venture under new ticker symbol "FTHW".First day of trading for both Reunion and Field Trip H&W is August 17, 2022.On July 21, 2022, announced successful first dosings in the Company's Phase 1 Clinical Study of its first novel psy

      8/15/22 5:09:58 PM ET
      $FTRP
    • Field Trip Announces Closing of Plan of Arrangement and $19.9 Million Private Placement Financing

      - Field Trip Health Ltd. has been renamed "Reunion Neuroscience Inc." and remains listed on the NASDAQ Stock Market and Toronto Stock Exchange under the ticker symbol "FTRP" with such ticker symbol changing to "REUN"- Field Trip Health & Wellness Ltd. to be listed on the TSX Venture Exchange under ticker symbol "FTHW" - First day of trading for both Reunion and Field Trip Health & Wellness expected to occur on or about August 17, 2022 - Field Trip Health & Wellness Ltd. completes $19.9 million private placement financing TORONTO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., (formerly, Field Trip Health Ltd.) (TSX:FTRP, NASDAQ:FTRP) (the "Company"), and Field Trip Health &

      8/11/22 4:28:21 PM ET
      $FTRP

    $FTRP
    SEC Filings

    See more
    • SEC Form 6-K filed by Field Trip Health Ltd.

      6-K - Reunion Neuroscience Inc. (0001865482) (Filer)

      1/9/23 7:35:40 AM ET
      $FTRP
    • SEC Form 6-K filed by Field Trip Health Ltd.

      6-K - Reunion Neuroscience Inc. (0001865482) (Filer)

      1/4/23 4:32:30 PM ET
      $FTRP
    • SEC Form 6-K filed by Field Trip Health Ltd.

      6-K - Reunion Neuroscience Inc. (0001865482) (Filer)

      11/28/22 4:55:14 PM ET
      $FTRP

    $FTRP
    Leadership Updates

    Live Leadership Updates

    See more
    • Field Trip Health Ltd. to Pursue Treatment Resistant Depression and Postpartum Depression as Indications for FT-104

      TORONTO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX:FTRP, FTRP.WT, NASDAQ:FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today the lead indications for FT-104, its novel psychedelic compound in development, will be Treatment Resistant Depression (TRD) and Postpartum Depression (PPD). Field Trip today also announced that Anita H. Clayton, MD, Chair of Psychiatry and Neurobehavioral Sciences at the School of Medicine at the University of Virginia, has joined its Scientific Advisory board. Through Field Trip Discovery, its drug development division, Field Trip is developing next-generation psychedelic molecu

      9/9/21 7:30:00 AM ET
      $FTRP

    $FTRP
    Financials

    Live finance-specific insights

    See more
    • Reunion Neuroscience Inc. (Formerly Field Trip Health Ltd.) Reports Fiscal First Quarter 2023 Financial Results, Completed Corporate Reorganization on August 11, 2022

      Completed corporate reorganization, separating the Field Trip Discovery and Field Trip Health divisions into two separate companies.Field Trip Discovery renamed Reunion Neuroscience Inc. ("Reunion" or the "Company"), and will remain listed on the NASDAQ Stock Market and Toronto Stock Exchange under new ticker symbol "REUN".Field Trip Health renamed Field Trip Health & Wellness Ltd. ("Field Trip H&W") and has received listing approval from the Toronto Stock Exchange Venture under new ticker symbol "FTHW".First day of trading for both Reunion and Field Trip H&W is August 17, 2022.On July 21, 2022, announced successful first dosings in the Company's Phase 1 Clinical Study of its first novel psy

      8/15/22 5:09:58 PM ET
      $FTRP
    • Field Trip Health Ltd. Schedules Fiscal First Quarter 2023 Conference Call for Tuesday, August 16, 2022, at 8:30 AM ET

      TORONTO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX:FTRP, NASDAQ:FTRP) ("Field Trip" or the "Company"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for its fiscal 2023 first quarter for the three-month period ended June 30, 2022, after market close on Monday, August 15, 2022. The Company will conduct a conference call and webcast to discuss its results the following morning, Tuesday, August 16, 2022 at 8:30 a.m. ET. To access the call, please dial 1-877-407-9716 (within the U.S.) or 1-201-493-6779 (outside the U.S.) and provide conference ID 13731900. A live webcast of the conferenc

      8/8/22 8:00:00 AM ET
      $FTRP
    • Field Trip Health Ltd. Reports Fiscal Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Including Corporate Reorganization

      Completed strategic review and announced intention to separate the Field Trip Discovery and Field Trip Health divisions into two independent public companies.Earned patient services revenues of $1.7 million in fiscal fourth quarter, an increase of 26.7% over the prior quarter and 228% year over year. Full year patient services revenue was $4.9 million, up from $0.96 million in the same period of the prior year.At March 31, 2022, Field Trip had approximately $63.7 million in unrestricted cash and cash equivalents.On April 5, 2022, granted U.S Patent for the first novel psychedelic molecule in development, molecule FT-104, for exclusive rights for the composition of matter, use and manufacturi

      6/29/22 10:00:50 PM ET
      $FTRP